trial

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

NCTId NCT04865835
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 21 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2022-05-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
21 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Single
Start
2021-05-12
Primary completion
2022-05-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
UlotarontMetformin

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

2 total
Oakland Park, United StatesMarlton, United States

Facts & assertions

4 sourced
Enrollment
21
Phase
PHASE1
Primary Completion Date
2022-05-03
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
Metformin
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication